Melior Signs Option Agreement with Pfizer
EXTON, Pa. (Business Wire EON) June 25, 2008 --
Melior Discovery, Inc. announced today that it has signed an option
agreement that provides Pfizer Inc the exclusive right to negotiate a
license to MLR-1023, Melior’s drug candidate
for Type II diabetes. In exchange, Pfizer agreed to make an undisclosed
payment to Melior and provide access to certain data it owns related to
MLR-1023. In addition, Melior agreed to utilize its in-vivo theraTRACE®
indications discovery platform to evaluate the activity of selected
Pfizer compounds in partnership with Pfizer.
”This is the second collaboration initiated
with Pfizer in the last 18 months and we look forward to this expansion
to our productive research and development relationship,”
said Andrew Reaume, PhD, President and CEO of Melior.
Melior Discovery Overview
Melior Discovery is leading the transformation of pharmaceutical drug
repositioning with its unique theraTRACE®
platform of multiplexed in vivo models. It is using this
capability to both build an internal pipeline of development candidates
as well as sharing this capability with pharma and biotechnology company
partners. In the former case, Melior is identifying “privileged”
compounds that have been discontinued by others which it identifies
through a close working relationship with Dr. Christopher Lipinski. In
its partnered arrangements, Melior offers pharmaceutical partners an
approach to expand their late-stage pipelines with safe, high-quality
drug candidates.
Melior Discovery is located in Exton, PA.
Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/Q291cC1UaGlyLVN1bW0tU2luZy1FbXB0LVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
